Montanus...I agree as I have a bunch of shares and bought more when it went below $.02. The risk is worth the reward and with ViroPharma and Lonza involved with Intellect this could be the year for ILNS! Just need to be patient and wait for Pfizer litigation to conclude and balance of year more progression of results from these players will push the PPS much higher. ILNS market cap is a really way undervalued when you look at ViroPharma and Lonza royalty potential alone! JMHO!